Literature DB >> 21277720

Advantage of early induction of opioid to control pain induced by irradiation in head and neck cancer patients.

Hisamitsu Takase1, Toshifumi Sakata, Takafumi Yamano, Takayuki Sueta, Satoshi Nomoto, Takashi Nakagawa.   

Abstract

OBJECTIVE: Although radiotherapy is effective for head and neck cancer patients, the local pain evoked by the irradiation itself reduces food intake and frequently halts the treatment. Thus, pain control is an important problem in radiotherapy for head and neck cancer. We performed to examine whether early induction of low-dose, opioid from mild pain improves dietary and caloric intake, while reducing weight loss.
METHODS: The subjects were 43 patients who were hospitalized for head and neck cancer from 2004 to 2008. They were patients who underwent radiation treatment but those who did not undergo preoperative treatment. They were divided into two groups, depending on whether the pain was mild or moderate when an opioid was introduced (MILD and MODERATE, N=23 and 20, respectively).
RESULTS: The visual analog scale scores for pain were significantly lower in the MILD than in the MODERATE group at between 25 and 50 Gy. The amount of oxycodone used for pain was significantly lower in the MILD than the MODERATE group. A regular diet was maintained for significantly longer in the MILD group. Caloric intake was significantly higher in the MILD group at over 20 Gy. Weight loss was significantly lower in the MILD group at over 20 Gy. The incidence of side effects was equal in both groups.
CONCLUSION: Our results indicated that the introduction of opioids for mild pain during radiotherapy controls the level of pain, improving food intake in head and neck cancer patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277720     DOI: 10.1016/j.anl.2010.12.012

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  3 in total

1.  Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial.

Authors:  Xin Hua; Lin-Min Chen; Qian Zhu; Wen Hu; Chao Lin; Zhi-Qing Long; Wen Wen; Xiao-Qing Sun; Zi-Jian Lu; Qiu-Yan Chen; Dong-Hua Luo; Rui Sun; Hao-Yuan Mo; Lin-Quan Tang; Wen-Wen Zhang; Zhen-Yu He; Hai-Qiang Mai; Huan-Xin Lin; Ling Guo
Journal:  Support Care Cancer       Date:  2019-02-02       Impact factor: 3.603

2.  A systematic review of the risk factors for clinical response to opioids for all-age patients with cancer-related pain and presentation of the paediatric STOP pain study.

Authors:  Ersilia Lucenteforte; Laura Vagnoli; Alessandra Pugi; Giada Crescioli; Niccolò Lombardi; Roberto Bonaiuti; Maurizio Aricò; Sabrina Giglio; Andrea Messeri; Alessandro Mugelli; Alfredo Vannacci; Valentina Maggini
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

Review 3.  Role of Oxycodone Hydrochloride in Treating Radiotherapy-Related Pain.

Authors:  Yinxia Wang; Ligang Xing
Journal:  Pain Res Manag       Date:  2020-01-30       Impact factor: 3.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.